Ravulizumab Sustains Improvement in Patients With Generalized Myasthenia Gravis
Researchers reported results from an interim analysis of an ongoing open-label extension to study the safety and efficacy of adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.